{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:38:46Z","timestamp":1787236726292,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the incidence, type, interval for reactivation, and structural outcomes in infants with aggressive retinopathy of prematurity (A-ROP) treated with ranibizumab or bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>It is a single-center, retrospective, consecutive, case series. We included infants with A-ROP which were initially treated with either intravitreal ranibizumab (IVR, 0.25 mg) or intravitreal bevacizumab (IVB, 0.625 mg) between January 2017 and December 2023. The infants were followed up for reactivation. The demographic and clinical data were collected. The time, zone, type of reactivation, its treatment, type of final structural outcome, and factors associated with reactivation were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred eight among the 322 infants with A-ROP were included in the study. Fifty-five received IVR, while 53 received IVB. Infants treated with IVR had higher incidence of reactivation (92.7% vs 52.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) at an earlier interval than IVB (7.7 weeks vs 12.8 weeks,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Infants treated with IVR had approximately 3.3 times higher possibility of reactivation than those treated with IVB. Three infants (5.9%) in the IVR group and five (9.4%) in the IVB group attained complete vascularization of the retina (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.72). More infants treated with IVB had regression with a persistent avascular retina (PAR) than IVR (52.8% vs 15.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Infants in the IVB group had 10 times higher possibility of regression with PAR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Infants of A-ROP treated with IVR have a higher incidence and earlier reactivation, while those treated with IVB have less incidence and delayed reactivation, albeit with a higher possibility of regression with a PAR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_161_24","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:01:34Z","timestamp":1726023694000},"page":"S119-S125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series"],"prefix":"10.4103","volume":"73","author":[{"given":"Anil Babanrao","family":"Gangwe","sequence":"first","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuzo B","family":"Ekumankama","sequence":"additional","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singh","sequence":"additional","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil Madhukar","family":"Parchand","sequence":"additional","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Cornea and Anterior Segment Services, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Vardhan","family":"Azad","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Indira Gandhi Institute of Medical Sciences and Raj Eye Care and Retina Centre, Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"R1-20260424","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, Third Edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R2-20260424","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1136\/fetalneonatal-2011-301121","article-title":"Aggressive posterior retinopathy of prematurity in large preterm babies in South India","volume":"97","author":"Shah","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R3-20260424","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4103\/IJO.IJO_232_23","article-title":"Comment on: Evaluation of clinical profile and screening guidelines of retinopathy of prematurity in an urban level III neonatal intensive care unit","volume":"71","author":"Gangwe","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2012.07.012","article-title":"Aggressive posterior retinopathy of prematurity: Risk factors for retinal detachment despite confluent laser photocoagulation","volume":"155","author":"Sanghi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R5-20260424","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcjo.2018.03.005","article-title":"Posterior zone I retinopathy of prematurity: Spectrum of disease and outcome after laser treatment","volume":"54","author":"Katoch","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.4103\/ijo.IJO_2581_20","article-title":"Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity","volume":"69","author":"Parchand","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4103\/ijo.IJO_200_21","article-title":"Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society","volume":"69","author":"Gangwe","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2022.07.009","article-title":"Practice patterns and outcomes of intravitreal anti-VEGF injection for retinopathy of prematurity: An International multicenter study","volume":"129","author":"Patel","year":"2022","journal-title":"Ophthalmology"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1120672119886989","article-title":"Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity","volume":"31","author":"Sahinoglu-Keskek","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of Bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in Retreatments between Bevacizumab and Ranibizumab intravitreal injections for retinopathy of prematurity: A multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity: Clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_161_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:37Z","timestamp":1786647157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_161_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":18,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_161_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"2024-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}